Novartis resumes production and delivery of radioligand therapy medicines ahead of schedule
Novartis provides update on production of radioligand therapy medicines
Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
ESMO (European Society of Medical Oncology) Congress
ASCO (American Society of Clinical Oncology) Annual Meeting
19th Annual ENETS Conference
ASCO Genitourinary Cancers Symposium
ASCO Gastrointestinal Cancers Symposium
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021